title: [On general practitioners' care of patients with asthma].
abstract: This review offers readers new aspects for the guideline-compliant care of asthma patients. Here, attention is focused on illustrating the bottlenecks in the administration of good and practicable therapeutic care and listing these as "major challenges for GPs". The interdisciplinary team of authors - consisting of three hospital-based pulmonologists, one pulmonologist in private practice, one internist in general practice, one pharmacist and one health economist discussed aspects of asthma therapy relevant in clinical practice.
  
  
  CONCLUSIONS
  Practicable results for the reader included an asthma pentagram, a graphic depicting the links and interactions between diagnosis, symptom management, communication, application and costs. From this emerged a consensus on four recommendations that can help GPs improve their care of their patients: (1) Whenever possible, have a specialist verifythe diagnosis. (2) Practice inhalation techniques with the patient and check up on their technique at regular intervals. (3) Monitor and fine-tune the therapeutic goals set down together with the patient. (4) Clearly define the (patient's) responsibilities and who is organizing care (communication between GP-specialist-patient-pharmacist-family members).
authors: Med. Klinik III, Pneumologie, Allergologie, Zentrum für Schlafund Beatmungsmedizin. th.voshaar@bethanienmoers.de
authors: T
authors: T
authors: Von Voshaar
authors: J
authors: J
authors: Behr
authors: B
authors: B
authors: Brüggenjürgen
authors: A
authors: A
authors: Deimling
authors: M
authors: M
authors: Krüger
authors: C
authors: C
authors: Virchow
authors: C
authors: C
authors: Wiens
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D058666:Adrenergic beta-2 Receptor Agonists / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D016535:Bronchial Hyperreactivity / Q000175:diagnosis / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology; D003362:Cost-Benefit Analysis / Q000191:economics; D003430:Cross-Sectional Studies; D003692:Delayed-Action Preparations / Q000191:economics; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000191:economics; D058006:General Practice / Q000191:economics; D005858:Germany; D006801:Humans; D008176:Lung Volume Measurements; D009313:National Health Programs / Q000191:economics; D009330:Nebulizers and Vaporizers / Q000191:economics; D010353:Patient Education as Topic / Q000191:economics; D010817:Physician-Patient Relations; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D058666:Adrenergic beta-2 Receptor Agonists; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D003692:Delayed-Action Preparations